Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the loss of immunotolerance to nucleic acids, the activation of autoreactive lymphocytes, and the production of large quantities of self-reactive antibodies that induce tissue damage 1 . Renal autoantibody deposition and lymphocyte infiltration lead to nephritis, a serious complication of lupus that presents in the clinical course of up to 60% of patients 2 . A hallmark of SLE is the production of type I interferons in response to immunocomplexes (ICs) containing self DNA from dead cells and DNA-specific immunoglobulin G (IgG) 3 . There is now a mounting body of evidence indicating that plasmacytoid dendritic cells (pDCs) are the main producers of pathogenic type I interferons in SLE 4 . pDCs are cells of the immune system that specialize in antiviral responses 5 . After sensing viral nucleic acids through the Toll-like receptors TLR7 (which senses RNA) and TLR9 (which senses DNA), pDCs release up to 1,000 times more type I interferons than any other cell type releases 6 , which promotes the cellular expression of interferonstimulated genes and the apoptosis of infected cells. Although TLR9 binds indiscriminately to both viral DNA and endogenous host DNA, its intracellular localization within endo-lysosomal compartments prevents the recognition of self DNA. In SLE, DNA-specific autoantibodies bind to endogenous DNA (released from damaged cells) and form DNA-containing ICs; these are then internalized by pDCs via the FcγRIIa receptor for IgG 7 , a process that allows delivery of self DNA to TLR9 within pDCs, which triggers an aberrant antiviral response. The recognition of self DNA by TLR9 leads to recruitment of the adaptor MyD88 and then to activation of the transcription factors NF-κB and IRF7, which induce the secretion of proinflammatory cytokines (such as TNF) and large amounts of type I interferons, respectively 8, 9 . Activation of TLR9 also induces the migration of pDCs and their ability to activate T cell and B cells, which positions pDCs at the crossroads of both innate immune responses and adaptive immune responses 10 .
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Published evidence has demonstrated that double-stranded DNA (dsDNA)-specific antibodies of the IgE immunoglobulin class are also present in some patients with SLE [11] [12] [13] , and although they have been associated with the activation of basophils 12, 14 , their role in disease pathogenesis has remained unclear. Found only in mammals, IgE is the least abundant immunoglobulin isotype and signals through two types of Fc fragment receptors: the high-affinity receptor FcεRI and the low-affinity receptor FcεRII. IgE provides protection against parasitic worms (helminths) but also triggers vigorous harmful, even deadly, allergic reactions to innocuous foreign proteins (allergens) 15, 16 . In both of these cases, IgE recognizes exogenous antigens and triggers an immunological response that is associated with the degranulation of mast cells and the subsequent release of biogenic amines and lipid mediators, the production of cytokines of the T H 2 subset of helper T cells (such as interleukin 4 (IL-4), IL-5 and IL-13), and eosinophilia 15 . Paradoxically, none of these inflammatory responses are key drivers of the pathogenesis of SLE 11, 17, 18 , and patients with SLE do not appear to be more prone to IgE-driven environmental allergies than is the general population [19] [20] [21] . Thus, it is plausible that self-reactive IgE in autoimmunity might have functions different from those described for IgE in helminth defense and allergy. To explore this, we investigated the potential roles of DNA-specific IgE in the pathogenesis of SLE.
RESULTS

IgE-triggered secretion of interferon- in SLE
In the SLE cohort we studied, 98 of 180 patients (54.4%) exhibited detectable concentrations of dsDNA-specific IgE, while healthy subjects, as well as patients with atopic dermatitis (a disease associated with elevated concentrations of IgE in serum), were all negative for this autoantibody (Fig. 1a) . The amount of circulating dsDNAspecific IgE was increased particularly in active disease (Fig. 1b) , and this correlated with small amounts of the complement component C3, a serological marker of disease activity 13, 22 (Fig. 1c) . To investigate the role of dsDNA-specific IgE in SLE, we explored whether these autoantibodies were able to modulate the type I interferon response. Activation of FcεR on pDCs by heat-aggregated IgE inhibited influenza virus-induced secretion of interferon-α (IFN-α) ( Supplementary  Fig. 1 ), a mechanism believed to explain the impaired IFN-α response observed for pDCs in atopic patients [23] [24] [25] . Therefore, the production of self-reactive IgE in patients with SLE with active disease might be a protective immunological mechanism for limiting exacerbated interferon responses and for diminishing inflammation. To test this hypothesis, we stimulated peripheral blood mononuclear cells (PBMCs) with serum from dsDNA-IgE + patients with SLE, in the presence of an IgE-blocking antibody that interferes with the binding of this immunoglobulin to its receptor. Unexpectedly, blockade of IgE did not increase IFN-α secretion by PBMCs but instead reduced its production (Fig. 1d) , which indicated that IgE might have actively contributed to the aberrant interferon responses in these patients. To assess if IgE autoantibodies were associated with clinical manifestations, we conducted a multivariate regression analysis using the general linear model, with the SLE disease activity index (SLEDAI) score as the dependent variable. According to this model, the concentration of dsDNA-specific IgE was a risk factor for SLE activity independently of the concentration of dsDNA-specific IgG ( Table 1) . Together these results suggested that these IgE autoantibodies found in SLE potentiated type I interferon responses and represented a previously unknown culprit that contributed to the aberrant secretion of interferon that underlies the pathogenesis of SLE.
Sensing of dsDNA-specific IgE by pDCs To gain mechanistic insight into how the self-reactive IgE found in SLE might contribute to this disease pathology, we engineered the variable regions of a previously described dsDNA-specific IgG (IgG D ) onto an IgE backbone that maintained specificity for dsDNA (IgE D ) ( Supplementary Fig. 2a,b) . As expected, IgE D showed dose-dependent binding to plate-bound DNA (Supplementary Fig. 2c ). IgE D induced secretion of IFN-α by pDCs in a concentration-dependent manner when combined with DNA, but an isotype-matched control IgE (IgE I ) did not (Fig. 2a) ; this demonstrated that ICs formed by IgE D and DNA were able to elicit interferon responses. Moreover, DNA-IgE ICs induced amounts of IFN-α similar to those induced by DNA-IgG ICs (Fig. 2b) . Notably, the IgE-blocking antibody did not affect the production of IFN-α induced by DNA-IgG ICs in pDCs, while it completely inhibited IFN-α production in cells stimulated with DNA-IgE ICs (Fig. 2c) . Together these findings demonstrated that dsDNA-specific IgE similar to that found in SLE was able to trigger the production of large quantities of IFN-α by pDCs.
To investigate the mechanisms leading to the activation of pDCs mediated by dsDNA-specific IgE, we first evaluated the cell-surface expression of both its high-affinity receptor (FcεRI) and its low-affinity receptor (FcεRII). We found that pDCs expressed only FcεRI (Fig. 3a) . Ectopic expression of human FcεRI by mouse macrophages was required for a marked increase in recruitment of the DNA receptor TLR9 to particles coated with DNA-IgE D ICs (Fig. 3b) , which indicated that FcεRI at the cell surface facilitated the delivery of DNAIgE D into a phagosomal compartment, where the engulfed DNA could be sensed. TLR9 triggers IRF7-dependent secretion of IFN-α from mature compartments positive for the lysosome marker LAMP-1 (refs. 26,27) . Therefore, we further explored the subcellular localization of DNA-IgE D ICs within the cell. DNA-IgE D ICs localized together with LAMP-1 in pDCs after internalization of the ICs (Fig. 3c) . This was associated with translocation of IRF7 to the nucleus (Fig. 3d) and with secretion of IFN-α that was completely blocked by inhibitors of TLR9 (Fig. 3e) . DNA-IgE D ICs also triggered secretion of the proinflammatory cytokines TNF, IL-8 and IL-6 in a TLR9-dependent manner ( Supplementary Fig. 3a-c) . These findings showed that DNA-IgE ICs engaged with FcεRI at the cell surface, which then delivered the complexes into mature compartments, where TLR9 sensed the DNA. In this intracellular compartment, TLR9 initiated a complex inflammatory response characterized by 
IgE deposits in SLE kidney biopsies
We found that 54.4% of patients with SLE in our cohort presented with dsDNA-specific IgE (Fig. 1a) . We then sought to determine whether any disease subset in our cohort showed particular enrichment for these autoantibodies and found that they were most frequent in patients with kidney manifestations. 70% of patients diagnosed with lupus nephritis (LN) had detectable concentrations of dsDNAspecific IgE (Fig. 4a) . Patients diagnosed with the most severe and common subtype of LN (diffuse proliferative nephritis; LN class IV) showed further enrichment for dsDNA-specific IgE, with a large majority of the patients (82%) having detectable levels of dsDNAspecific IgE (Fig. 4b) . As previously shown for IgG 28, 29 , IgE deposits were present in both glomerular areas and extraglomerular areas ( Fig. 4c and Supplementary Fig. 4a,b) . IgE was deposited similarly in both areas, while IgG deposits were present mainly in glomerular structures ( Fig. 4c and Supplementary Fig. 4a,b) . pDC infiltrates were present in glomerular and extraglomerular areas, with larger infiltrates of pDCs in the glomeruli ( Fig. 4c and Supplementary  Fig. 4a,b) . However, we did not detect substantial infiltration of basophils, a cell type that responds to IgE and has been linked to SLE 12 , in either LN kidneys or normal kidneys (data not shown). MxA, a protein produced in response to the secretion of type I interferons, was expressed mainly in the glomeruli of biopsies from patients with LN, with a distribution similar to that of pDCs ( Fig. 4c and Supplementary Fig. 4a,b) . This suggested that infiltrating pDCs were able to interact directly with and become activated by local ICs containing nucleotides able to trigger TLR7-and/or TLR9-dependent stimulation. As circulating IgG and IgE autoantibodies have equal access to exposed nucleic acid autoantigens shed by dead cells in tissues, the interferon response we visualized as MxA positivity in the kidney biopsies was probably driven by ICs that simultaneously contained immunoglobulins of both classes. Therefore, we concluded from these experiments that IgE autoantibodies deposited in renal glomeruli during lupus could potentially contribute to local inflammatory processes.
B cell responses triggered by DNA-IgE-stimulated pDCs
We also observed areas of kidney biopsies of patients with LN in which both pDCs and B cells were present in close proximity (Fig. 5a) . pDCs can induce the proliferation of B cells and the differentiation of B cells into plasma cell (PCs) 30 . Therefore, we investigated the ability of dsDNA-specific IgE to stimulate PC differentiation in a pDC-B cell co-culture system, using purified human pDCs and B cells. The addition of DNA-IgE D ICs led to a marked increase in the number of B cells (Fig. 5b) , the differentiation of B cells into PCs (Fig. 5c ) and the secretion of IgM (Fig. 5d) . B cell responses were dependent on the presence of pDCs in the co-cultures, as stimulation of B cells alone with the ICs did not result in any increase in cell number or PC formation ( Supplementary Fig. 5a-c) . During infection, two of the cytokines secreted by pDCs act sequentially on B cells to trigger their differentiation into PCs, with IFN-α generating plasmablasts that do not secrete immunoglobulins, and IL-6 inducing their final differentiation into immunoglobulin-secreting PCs 30 . We therefore investigated whether these soluble factors were required for the generation of PCs in response to the IgE-containing ICs. Inhibiting the type I interferon receptor IFNAR or inhibiting IL-6 with blocking antibodies resulted in a marked reduction in the formation of PCs in the co-cultures treated with DNA-IgE D ICs (Fig. 5e) . Collectively, these results demonstrated that ICs containing dsDNA-specific IgE were able to lead to pDC-mediated activation of B cells, a mechanism that might exacerbate the B cell-driven autoimmune response in the kidneys of patients with LN.
Synergy of IgE ICs and IgG ICs
In the SLE cohort we studied, circulating dsDNA-specific IgE correlated with dsDNA-specific IgG (Fig. 6a) . Notably, all patients whose serum contained dsDNA-specific IgE also tested positive for dsDNA-specific IgG, with no patient being positive for the IgE isotype alone (Fig. 6a) . As exposed DNA from damaged cells is accessible to both dsDNA-specific IgG and dsDNA-specific IgE in the circulation, patients probably form pathogenic ICs that simultaneously contain both classes of immunoglobulins. That concept is consistent with the finding of deposits of both IgG autoantibodies and IgE autoantibodies in glomerular and tubular areas of biopsies from patients with LN ( Fig. 4c and Supplementary Fig. 4a,b) . For this reason, we investigated the effect of ICs containing DNA plus IgG and IgE on pDC responses. We found that combining both isotypes at a ratio npg of 1:1 resulted in the formation of complexes that triggered much greater secretion of IFN-α than that triggered by complexes containing a single immunoglobulin isotype (Fig. 6b) . This combination also increased secretion of the proinflammatory cytokines TNF, IL-6 and IL-8 ( Supplementary Fig. 6a-c) . We monitored the intracellular production of IFN-α and TNF by stimulated pDCs for 16 h and observed that the elevated concentrations of IFN-α (Fig. 6c) and TNF ( Fig. 6d) were due largely to an increase in the frequency of cells secreting these cytokines. We noted the peak of production was at 6 h, when most cells were co-expressing both cytokines (Fig. 6e) . pDCs exposed to DNA-IgE D ICs also had a phenotype more mature than that of unstimulated cells, with robust expression of the cell-surface co-stimulatory molecules CD83 and CD86 (Fig. 6f) . (Fig. 6f) . We observed the same result for expression of CCR7, a chemokine receptor used by mature pDCs to migrate into lymphoid compartments 31 (Fig. 6f) . Furthermore, DNA-IgE D ICs induced robust migration of pDCs to ligands of CCR7 to a significantly greater degree than the migration triggered by ICs formed with IgG D (Fig. 6g) . Antigen presentation is a central feature of autoimmune disorders such as SLE, and DNA-IgE D ICs were able to trigger antigen-specific secretion of IFN-γ (Fig. 6h) and T cell proliferation (Fig. 6i) in pDC-T-cell co-cultures. In these co-cultures, DNA-IgE D ICs and DNA-IgG D ICs produced responses similar in magnitude and acted in synergy when combined.
From these experiments, we concluded that DNA-IgE ICs were able to trigger the secretion of proinflammatory cytokines, maturation, migration and antigen presentation by pDCs. In all cases, the responses were similar to or larger than those initiated by DNA-IgG complexes. Combining both IgG and IgE in the complexes resulted in synergistic secretion of inflammatory cytokines, including IFN-α, in pDCs. This was not due to greater secretion per cell but instead to a larger number of cells responding to the ICs, which indicated that the presence of IgE in these complexes lowered the threshold for triggering pDC responses.
Enhancement of IC phagocytosis by IgE
Although we detected dsDNA-specific IgE in a majority of patients with SLE, the concentration of dsDNA-specific IgE in the circulation was, on average, about 20 times lower than concentration of the corresponding IgG (Fig. 7a) . Hence, we investigated the relative contribution of IgE to interferon responses in conditions similar to those found in patients. For this, we prepared DNA-containing ICs with a fixed amount of DNA-IgG D and assessed the effect of adding increasing amounts of IgE D on the secretion of IFN-α. Strikingly, the addition of even small amounts of IgE D to the complexes greatly enhanced the amount of IFN-α produced by pDCs (Fig. 7b) . This was true even when the concentration of IgE was 100 times lower than that of IgG in the ICs, under which circumstances the presence of IgE enhanced the interferon response more than fivefold (Fig. 7b) . We obtained similar results for complexes formed in vitro with U1 small nuclear ribonucleoprotein particles, an RNA-associated autoantigen found in SLE 32 (Fig. 7c,d) , which indicated that the role of IgE in SLE might not only be restricted to DNA but also expand to autoantigens sensed by TLR7. To understand mechanistically how IgE enhanced the secretion of IFN-α, we investigated its effect on the phagocytic uptake of ICs, through the use of fluorescence-labeled DNA. The frequency of pDCs with detectable uptake of intracellular DNA was similar when either IgG D or IgE D was used to form the ICs (Fig. 7e,f) . However, the combination of IgE D and IgG D induced synergistic phagocytosis when combined at a ratio of 1:1 (Fig. 7e,f) . This synergy was maintained even in conditions under which the amount of IgE D used was 10-or 100-fold lower than that of IgG D (similar to the ratios found in patients with SLE) (Fig. 7e,f) . The number of pDCs with detectable phagosomal DNA at those two ratios were 5.11-fold higher and 2.97-fold higher, respectively, than that of pDCs with detectable phagosomal DNA when ICs formed with only IgG D were used (Fig. 7g) . These results indicated that the enhanced secretion of IFN-α triggered by low concentrations of IgE D was caused by substantially greater IC phagocytosis. This mechanism would also explain how more cells secreted pathogenic IFN-α when stimulated with DNA-ICs containing both IgG and IgE than when stimulated with ICs formed with single immunoglobulins (Fig. 6c) , as the presence of dsDNA-specific IgE in the ICs lowered the threshold for triggering pDC responses.
DISCUSSION
Measures to limit the exposure of host DNA to the nucleic-acid sensor TLR9 are critical for maintaining tolerance to self. One such protective measure is the compartmentalization of TLR9 to intracellular membranes, which restricts this receptor's access to circulating free DNA and thus limits inappropriate responses to self. Notably, cellsurface expression of TLR9 on hematopoietic stem cells results in lethal autoinflammatory disease in mice 33 , which highlights the importance of maintaining TLR9 within the cell. Here we demonstrated that the DNA-IgE autoantibodies found in SLE undermined 
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A r t i c l e s those aforementioned safeguards by shuttling self DNA to intracellular TLR9 via the activation of cell-surface FcεRI on pDCs. This mechanism parallels that used by IgG autoantibodies that, in contrast, utilize FcγRIIa to deliver DNA into the cell 7, 26 . Furthermore, we have provided evidence that IgE acted in synergy with IgG to induce more engulfment of DNA-containing ICs and that IgE enhanced pDC responses even when 100-to 1,000-fold less abundant in the ICs than IgG. One potential explanation for the potent synergistic activity of IgE in the DNA-containing ICs formed with both IgG and IgE might be that FcεRI binds monomeric IgE with an association constant of 10 10 M −1 (ref. 34) , which is at least three order of magnitude higher than the binding of IgG to the low-affinity receptor FcγRIIa 35 . Therefore, the ability of IgE to enhance the phagocytic capacity of pDCs might be a critical step in promoting the further loss of tolerance in these patients with SLE. This mechanism becomes even more important given the limited phagocytic potential of pDCs and the presence of nucleases in acidic organelles that digest and limit the amount of DNA available to be sensed by TLR9. Thus, IgE might facilitate the accumulation of DNA-containing ICs in the phagosome in concentrations that facilitate elicitation of TLR9-mediated pDC responses. Indeed, we found that the combined stimulation of pDCs with IgE ICs plus IgG ICs exacerbated the inflammatory response due to an increase in the frequency of cells responding to self DNA, rather than increased production of IFN-α or TNF per cell.
IgE is the least-abundant and least-well-understood immunoglobulin isotype in disease. Evidence obtained with animal models and statistical population trends suggests that IgE might be beneficial in fighting parasites, whereas IgE is believed to trigger harmful allergic reactions to innocuous foreign proteins 16, 36 . In both of these cases, IgE recognizes exogenous antigens and triggers an immunological response that is associated with the activation of mast cells and basophils, which results in degranulation and the subsequent release of biogenic amines, lipid mediators and T H 2 cytokines. The presence of IgE antibodies that bind endogenous host antigens in SLE has been known for some time. The characteristic IgE-mediated responses are not observed in SLE, and this has somewhat complicated elucidation of their role in a disease that is driven mainly by an aberrant antiviral response 5 . For example, dsDNA-IgE + patients with SLE do not exhibit higher concentrations of circulating IL-4 or IL-5 than do seronegative patients or healthy control subjects 37 . Instead, we found that the concentration of self-reactive dsDNA-IgE in serum correlated with disease severity and was a risk factor for SLE activity, regardless of the amount of IgG antibodies that bound the same autoantigens in our patient cohort. Furthermore, we demonstrated that dsDNA-specific IgE actively contributed to SLE by enhancing the specific immunological effects, including interferon secretion, associated with this disease. Collectively, the unexpected responses described here for IgE were unique and distinct from the classical T H 2-skewed responses observed in allergic disease.
That aforementioned link among IgE, autoimmunity and interferon responses revealed an unexpected concept for the physiological role of IgE in the immune system. Notably, we found that DNA-IgE ICs functionally affected pDCs by inducing maturation, antigen presentation, cellular migration and the secretion of IFN-α and other proinflammatory cytokines. In addition, these ICs also triggered pDC-dependent B cell responses and the population expansion of PCs. Notably, IgE acted in synergy with IgG even when present in the ICs at several orders of magnitude lower than IgG. Therefore, we propose that this robust activation of pDCs is deleterious in SLE, since the response is aberrantly generated against self nucleic acids.
Alternatively, robust pDC activity would be beneficial to the host if these cells were targeting viral particles. One possibility is that IgE acts together with IgG to facilitate sensing of viruses and to deliver their pathogenic nucleic acids to TLR7 and TLR9 within the phagosome. Studies of humans and animals have identified IgE antiviral antibodies in serum [38] [39] [40] . These antibodies seem to be driven by viral load, as reported by a study focused on respiratory syncytial virus. Notably, the concentration of IgE antibodies directed against respiratory syncytial virus correlates with that of their IgG counterpart, as well as with circulating viral protein F 39 . This is consistent with our observations of good correlation between anti-dsDNA IgE and anti-dsDNA IgG generated in response to autoantigens in SLE. There is also evidence suggesting that IgE directed against human immunodeficiency virus might be beneficial in controlling infection with this virus. Total IgE from patients seropositive for IgE antibodies to human immunodeficiency virus have been found to block viral production in PBMCs by mechanisms that exclude viral neutralization, which would suggest that these antibodies have antiviral properties by acting through cells of the immune sytem 38 . Furthermore, a small study has reported that IgE directed against human immunodeficiency virus in patients is not associated with a higher incidence of allergy 41 , which resembles findings of similar epidemiological studies of patients with SLE who are seropositive for dsDNA-IgE. How the mechanisms we have proposed for IgE in autoimmunity extend to scenarios of viral defense warrants further investigation. Nevertheless, the data presented here expand the physiological functions of IgE in the immune system and suggest that mammals' recent evolutionary acquisition of IgE might provide benefits to the host beyond defense against helminths.
In conclusion, the aberrant recognition of self nucleic acids is central to SLE, as it triggers an inflammatory response that ultimately leads to autoimmunity and tissue damage. The data presented here indicate previously unknown mechanisms for a pathogenic role of IgE in this disease and explain how the appearance of self-reactive IgE can exacerbate the inflammatory pathways that contribute to self-inflicted damage. The previously unrecognized link between IgE and the interferon pathway that we have reported here provides additional insight into the pathological mechanisms underlying autoimmunity and might be useful in the rational design of therapies for the treatment of diseases such as SLE.
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Methods and any associated references are available in the online version of the paper. 
